World J Oncol

World Journal of Oncology, ISSN 1920-4531 print, 1920-454X online, Open Access

Article copyright, the authors; Journal compilation copyright, World J Oncol and Elmer Press Inc

Journal website http://www.wjon.org

Original Article

Volume 8, Number 3, June 2017, pages 71-75

A Retrospective Analysis of Clinical Utility of AJCC 8th Edition Cancer Staging System for Breast Cancer

**Table 1.** Patients and Tumor Characteristics
Characteristic	N	%
Age, years
< 35	121	15.5%
≥ 35	663	84.5%
Menopausal status
Postmenopausal	98	12.5%
Premenopausal	686	87.5%
T stage at diagnosis
T1	292	37.2%
T2	439	56.0%
T3	35	4.5%
T4	18	2.3%
N status at diagnosis
N0	381	48.6%
N1	223	28.4%
N2	105	13.4%
N3	75	9.6%
M status at diagnosis
M0	764	97.4%
M1	20	2.6%
ER status
Positive	594	75.8%
Negative	190	24.2
PR status
Positive	513	65.4%
Negative	217	34.6%
HER2 status
Positive	238	30.4%
Negative	546	69.6%

Table 1. Patients and Tumor Characteristics

Characteristic

Age, years

< 35

121

15.5%

≥ 35

663

84.5%

Menopausal status

Postmenopausal

12.5%

Premenopausal

686

87.5%

T stage at diagnosis

292

37.2%

439

56.0%

4.5%

2.3%

N status at diagnosis

381

48.6%

223

28.4%

105

13.4%

9.6%

M status at diagnosis

764

97.4%

2.6%

ER status

Positive

594

75.8%

Negative

190

24.2

PR status

Positive

513

65.4%

Negative

217

34.6%

HER2 status

Positive

238

30.4%

Negative

546

69.6%

**Table 2.** Distribution of the Prognostic Stage and TNM Stage of the Patients
TNM stage	Prognostic stage
IA	125	42	21	0	0	0	0	0	0	188 (24.0%)
IIA	0	139	28	32	44	0	0	0	0	243 (31.0%)
IIB	0	17	1	0	25	23	14	0	77	157 (20.0%)
IIIA	0	14	4	59	11	10	4	0	0	102 (13.0%)
IIIB	0	0	0	0	0	3	4	0	0	7 (0.9%)
IIIC	0	0	0	0	2	31	34	0	0	67 (8.5%)
IV	0	0	0	0	0	0	0	20	0	20 (2.6%)
Total (%)	125 (15.9%)	212 (27.0%)	54 (6.9%)	91 (11.6%)	82 (10.5%)	67 (8.5%)	56 (7.1%)	20 (2.6%)	77 (9.8%)

Table 2. Distribution of the Prognostic Stage and TNM Stage of the Patients

TNM stage

Prognostic stage

IIA

IIB

IIIA

IIIB

IIIC

Unknown

Total

125

188 (24.0%)

IIA

139

243 (31.0%)

IIB

157 (20.0%)

IIIA

102 (13.0%)

IIIB

7 (0.9%)

IIIC

67 (8.5%)

20 (2.6%)

Total (%)

125 (15.9%)

212 (27.0%)

54 (6.9%)

91 (11.6%)

82 (10.5%)

67 (8.5%)

56 (7.1%)

20 (2.6%)

77 (9.8%)

**Table 3.** Change of TNM Stage and Prognostic Stage
TNM stage	Prognostic stage
Stage	N	Stage	N (%)
IA	188	IA	12 (66.5%)
		IB	42 (22.3%)
		IIA	21 (11.2%)
IIA	243	IB	13 (57.2%)
		IIA	28 (11.5%)
		IIB	32 (13.2%)
		IIIA	44 (18.1%)
IIB	157	IB	17 (10.8%)
		IIA	1 (0.6%)
		IIIA	25 (15.9%)
		IIIB	23 (14.6%)
		IIIC	14 (8.9%)
		Unknown	77 (49.0%)
IIIA	102	IB	14 (13.7%)
		IIA	4 (3.9%)
		IIB	59 (57.8%)
		IIIA	11 (10.7%)
		IIIB	10 (9.8%)
		IIIC	4 (3.9%)
IIIB	7	IIIB	3 (42.9%)
		IIIC	4 (57.1%)
IIIC	67	IIIA	2 (3.0%)
		IIIB	31 (46.3%)
		IIIC	34 (50.7%)
IV	20	IV	20 (100%)

Table 3. Change of TNM Stage and Prognostic Stage

TNM stage

Prognostic stage

Stage

N (%)

188

12 (66.5%)

42 (22.3%)

IIA

21 (11.2%)

IIA

243

13 (57.2%)

IIA

28 (11.5%)

IIB

32 (13.2%)

IIIA

44 (18.1%)

IIB

157

17 (10.8%)

IIA

1 (0.6%)

IIIA

25 (15.9%)

IIIB

23 (14.6%)

IIIC

14 (8.9%)

Unknown

77 (49.0%)

IIIA

102

14 (13.7%)

IIA

4 (3.9%)

IIB

59 (57.8%)

IIIA

11 (10.7%)

IIIB

10 (9.8%)

IIIC

4 (3.9%)

IIIB

3 (42.9%)

IIIC

4 (57.1%)

IIIC

IIIA

2 (3.0%)

IIIB

31 (46.3%)

IIIC

34 (50.7%)

20 (100%)

**Table 4.** Distribution of Prognostic Stage and Subtype
Stage	Luminal A	Luminal B HER2 positive	Luminal B HER2 negative	Triple negative	HER2-enriched	P value
IA	37 (42.0%)	26 (16.4%)	61 (17.1%)	0	1 (1.3%)	< 0.001
IB	31 (35.2%)	65 (40.9%)	99 (27.8%)	0	17 (22.1%)
IIA	3 (3.4%)	1 (0.6%)	21 (5.9%)	18 (17.3%)	11 (14.3%)
IIB	6 (6.8%)	18 (11.3%)	56 (15.7%)	0	11 (14.3%)
IIIA	0	10 (6.3%)	10 (2.8%)	40 (38.5%)	22 (28.6%)
IIIB	1 (1.1%)	17 (10.7%)	29 (8.1%)	18 (17.3%)	2 (2.6%)
IIIC	0	6 (3.8%)	16 (4.5%)	24 (23.1%)	10 (13.0%)
IV	1 (1.1%)	3 (1.9%)	9 (2.5%)	4 (3.8%)	3 (3.9%)
Unknown	9 (10.2%)	13 (8.2%)	55 (15.4%)	0	0
Total	88 (11.2%)	159 (20.3%)	356 (45.4%)	104 (13.3%)	77 (9.8%)

Table 4. Distribution of Prognostic Stage and Subtype

Stage

Luminal A

Luminal B HER2 positive

Luminal B HER2 negative

Triple negative

HER2-enriched

P value

37 (42.0%)

26 (16.4%)

61 (17.1%)

1 (1.3%)

< 0.001

31 (35.2%)

65 (40.9%)

99 (27.8%)

17 (22.1%)

IIA

3 (3.4%)

1 (0.6%)

21 (5.9%)

18 (17.3%)

11 (14.3%)

IIB

6 (6.8%)

18 (11.3%)

56 (15.7%)

11 (14.3%)

IIIA

10 (6.3%)

10 (2.8%)

40 (38.5%)

22 (28.6%)

IIIB

1 (1.1%)

17 (10.7%)

29 (8.1%)

18 (17.3%)

2 (2.6%)

IIIC

6 (3.8%)

16 (4.5%)

24 (23.1%)

10 (13.0%)

1 (1.1%)

3 (1.9%)

9 (2.5%)

4 (3.8%)

3 (3.9%)

Unknown

9 (10.2%)

13 (8.2%)

55 (15.4%)

Total

88 (11.2%)

159 (20.3%)

356 (45.4%)

104 (13.3%)

77 (9.8%)